CD8A and lupus nephritis: Taken together, we now reveal that CD8+CD103+ iTreg induced ex vivo significantly control the appearance and development of nephritis in lupus-like diseases; therefore, use of CD8+CD103+ iTregs may have a potential promise for the treatment of lupus nephritis and other autoimmune and inflammatory diseases.